Observational studyPloS one2022

Effects of immune checkpoint inhibitor therapy resumption in patients with malignant tumors after moderate-to-severe immune-related adverse events.

Machiko Kawahira et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.